
Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Ceretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510 Legislative Resource Center B-106 Cannon Building Washington, DC 20515



## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Bennett, Turner & Coleman, LLP		
2. Address Check if different than previously reported 1900 K Street NW, Suite 750 Was	hington, DC 20006	
3. Principal Place of Business (if different from time 2)		***************************************
City: State5	Zip (or Country)	
4. Consuct Name Telephone Albert Cacozza 202-833-4500	E-mail (optional)	5. Senate 1D#
7. Client Name		δ. House ID #
TYPE OF REPORT 8. Year 2000 Midyess  O. Check if this filing amends a previously filed version of this  O. Check if this is a Termination Report   Termination	report <b>Q</b>	ind (July 1-December 31)
INCOME OR EXPENSES - Complete Either	Line 12 OR Line 13	i
12. Lobbying Firms	13. Organiza	ions
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying active period were:	ities for this reporting
Less than \$10,000 <b>②</b>	Less than \$10,000 🗍	
	\$10,000 or more 🔲 🗢 s	<u></u>
\$10,000 or more \( \sum_{\text{income (nearest \$20,000)}} \)  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	Expenses (nearest \$20,000)  14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  Method A. Reporting amounts using LDA definitions only  Method B. Reporting amounts under section 6033(b)(8)of the Internal Revenue Code	
	Method C. Reporting amounts un Internal Revenue Cod	
Signature		
Printed Name and Title Terry S. Coleman, Partner		
LD-2 (REV, 6/98)		PAGE 1 or 2

Registrant Name Client Name	Novartis Pharmaceuticals Corporation	
LOBBYING ACTIVITY. Select as many codes as necessary engaged in lobbying on behalf of the client during the reportin information as requested. Attach additional page(s) as needed	g period. Using a separate page for each code, provid	t C
15. General issue area code MMM (one per page)		
16. Specific lobbying issues		
Medicare reimbursement for oral anti-cancer drug	) <b>8</b>	
17. House(s) of Congress and Federal agencies contacted	Check if None	
U.S. House of Representatives U.S. Senate		
18. Name of each individual who acted as a lobbyist in this is:	sive area	
Name	Covered Official Position (if applicable)	New
Sam Turner, Partner		
Elizabeth Goss, Partner		
	`~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
		<b>©</b>
		0
		0
		0
19. Interest of each foreign entity in the specific issues listed on time.  To the degree that public policies, either laws or regulations.  Corporation, so too Novartis AG will benefit. Novartis AG is Corporation and the parent benefits in the commercial succession.	, commercially benefit Novartis Pharmaceuticals the parent company of Novartis Pharmaceuticals	0
To the degree that public policies, either laws or regulations Corporation, so too Novartis AG will benefit. Novartis AG is	, commercially benefit Novartis Pharmaceuticals the parent company of Novartis Pharmaceuticals	0
To the degree that public policies, either laws or regulations Corporation, so too Novartis AG will benefit. Novartis AG is Corporation and the parent benefits in the commercial succe	, commercially benefit Novartis Pharmaceuticals the parent company of Novartis Pharmaceuticals ess of its subsidiary.	0